Nice Bro, i lke $ANX but dude u really have to look at $CLNT from here, called her off her 50day support. she will retest last high and has to push through her 50day resistance on the daily
Biotechs have been on fire lately, and I have been scouring through some Biotech that have yet to move. I have been acquiring shares of Sickle Cell biotech Adventrx Pharmaceuticals (ANX). Adventrx Pharmaceuticals' leading drug is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications from Sickle Cell disease. The study of ANX-188 in sickle cell disease has completed phase II drug testing and they are preparing for the phase 3 stage. The stock currently trades 20 percent below its cash position. As of the last quarter end, filed August 6th, the company has no debt and a strong cash position of over $43 million or .90 cents per share.
$665 Million Dollar Elephant
The discount to cash alone is reason to pounce on this undiscovered biotech. However the big reason I am long and so bullish on the stock is the recent $665 million agreement competitor Selexys Pharmaceuticals made with Novartis. Selexys Pharmaceuticals is a biotech whose leading drug also helps Sickle Cell disease and its drug is ready to begin a broader Phase 2 clinical study. Selexys has agreed to provide Novartis Pharmaceuticals, an exclusive option to buy Selexys and its developing drug called SelG1 after the successful completion of the Phase 2 study. The deal, which includes upfront, acquisition and milestone payments, could total up to $665 million.
The $665 million dollar price gives an idea of the value of this medical technology. Selexys Pharmaceuticals is still in Phase 2 stages compared to Adventrx which is commencing Stage 3. The current market cap for ANX is $36 million. In my opinion the Novartis deal made with Selexys is cheap and Adventrx knows it, as ANX-188 is not just beneficial for Sickle Cell disease but other diseases as well such as Acute Chest Syndrome and Hemorrhagic Shock. I have been accumulating shares at these levels and anxiously await further developments from the company.
Investors should take note, (or take under consideration), that this stock is considered a microcap stock and trades below a dollar per share. Trading in sub-dollar micro cap stocks can be a risk due to extreme volatility.
Market Data 
Markets 
AI
